Synlogic (SYBX) Q2 2024 earnings summary

Executive summary

• Discontinued lead Phase 3 trial (Synpheny-3) in February 2024 after internal review indicated it was unlikely to meet its primary endpoint; not due to safety concerns.

• Undertook a major corporate restructuring, reducing workforce by over 90% and shifting focus to evaluating strategic alternatives, including a potential merger or sale.

• Retained Lucid Capital Markets to explore strategic alternatives, including potential acquisition, merger, or business combination.

• No decisions or timetable set for the strategic review process.

• Pipeline now consists of early-stage and preclinical programs for rare metabolic diseases, with no ongoing pivotal clinical trials.

Financial highlights

• Net income of $2.0 million for Q2 2024, compared to a net loss of $15.0 million in Q2 2023, driven by restructuring gains.

• Cash and cash equivalents were $20.0 million as of June 30, 2024, down from $47.4 million at the end of 2023.

• Research and development expenses decreased to $2.2 million in Q2 2024 from $11.8 million in Q2 2023, reflecting the discontinued trial and workforce reduction.

• General and administrative expenses decreased to $1.2 million from $3.9 million year-over-year.

• No revenue for Q2 2024, compared to $35,000 in Q2 2023, reflecting the end of a Roche collaboration.

Outlook and guidance

• Current cash and cash equivalents expected to fund operations at current levels for at least the next 12 months.

• Expenses anticipated to decrease in the near term due to the discontinued clinical trial and reduced workforce.

• Exploring strategic alternatives to maximize shareholder value, with no assurance of a transaction.